Deutsche Bank AG Purchases New Stake in Humana Inc. $HUM

Key Points

• Deutsche Bank acquired 411,221 Humana shares during the second quarter, worth approximately $163.3 million and representing a 0.34% stake. Institutional investors collectively own 92.38% of the company.
• Analyst sentiment is mixed: 14 analysts rate Humana a Buy, 15 recommend Hold and one recommends Sell. The consensus rating is Hold, with an average price target of $395.22.
• Humana reported quarterly EPS of $7.61, exceeding the $7.27 estimate, while revenue rose 26.2% year over year to $40.89 billion. Shares opened at $377.18, near the consensus target.

Deutsche Bank AG acquired a new position in shares of Humana Inc. (NYSE:HUM - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 411,221 shares of the insurance provider's stock, valued at approximately $163,345,000. Deutsche Bank AG owned 0.34% of Humana at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Trust Co. of Vermont acquired a new position in shares of Humana during the 2nd quarter worth $28,000. Bogart Wealth LLC lifted its stake in shares of Humana by 192.0% in the second quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider's stock valued at $29,000 after purchasing an additional 48 shares during the period. Montag A & Associates Inc. boosted its holdings in Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock worth $25,000 after buying an additional 94 shares in the last quarter. Fideuram Asset Management Ireland dac purchased a new stake in Humana during the fourth quarter worth about $27,000. Finally, Reflection Asset Management acquired a new position in Humana during the fourth quarter worth about $29,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Analysts Set New Price Targets

HUM has been the subject of a number of research analyst reports. Barclays increased their target price on shares of Humana from $344.00 to $407.00 and gave the company an "equal weight" rating in a report on Friday, July 31st. Raymond James Financial cut Humana from an "outperform" rating to a "market perform" rating in a report on Thursday, July 30th. UBS Group initiated coverage on Humana in a research note on Thursday, July 30th. They issued a "buy" rating for the company. Evercore raised Humana from an "in-line" rating to an "outperform" rating and set a $480.00 price objective for the company in a report on Wednesday, July 29th. Finally, Needham & Company LLC initiated coverage on Humana in a research report on Wednesday, May 20th. They set a "buy" rating on the stock. Fourteen equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $395.22.

Humana Stock Performance

NYSE HUM opened at $377.18 on Thursday. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $428.88. The business has a fifty day moving average of $383.16 and a 200-day moving average of $279.59. The stock has a market cap of $45.29 billion, a price-to-earnings ratio of 35.68, a price-to-earnings-growth ratio of 2.18 and a beta of 0.72.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, beating analysts' consensus estimates of $7.27 by $0.34. The business had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.The business's revenue for the quarter was up 26.2% compared to the same quarter last year. During the same quarter last year, the company earned $6.27 earnings per share. As a group, analysts predict that Humana Inc. will post 9.08 earnings per share for the current fiscal year.

Humana Company Profile

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source